Chapter 7 Mechanisms of Arterial Calcification. Spotlight on The Inhibitors

Advances in Clinical Chemistry

Volumn 46, Issue , 2008, Pages 263-293

  Weissen Plenz, Gabriele ^a   Nitschke, Yvonne ^a   Rutsch, Frank ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2HS GLYCOPROTEIN; CALCIUM BINDING PROTEIN; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; INORGANIC PYROPHOSPHATASE; MATRIX GLA PROTEIN; OSTEOPONTIN; OSTEOPROTEGERIN; PHOSPHODIESTERASE; PLASMA PROTEIN; SCLEROPROTEIN; TNFRSF11B PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANIMAL; ARTERY; CALCINOSIS; HUMAN; INFLAMMATION; PATHOLOGY; PHYSIOLOGY; REVIEW; VASCULAR DISEASE;

ANIMALS; ARTERIES; BLOOD PROTEINS; CALCINOSIS; CALCIUM-BINDING PROTEINS; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INFLAMMATION; OSTEOPONTIN; OSTEOPROTEGERIN; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; VASCULAR DISEASES;

EID: 53849083453     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(08)00407-1     Document Type: Review

References (160)

1. Rajamannan N.M., Subramaniam M., Rickard D., Stock S.R., Donovan J., Springett M., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107 17 (2003) 2181-2184
2. Caira F.C., Stock S.R., Gleason T.G., McGee E.C., Huang J., Bonow R.O., et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 47 8 (2006) 1707-1712
3. Cario-Toumaniantz C., Boularan C., Schurgers L.J., Heymann M.F., Le Cunff M., Leger J., et al. Identification of differentially expressed genes in human varicose veins: Involvement of matrix gla protein in extracellular matrix remodeling. J Vasc Res 44 6 (2007) 444-459
4. Wilson P.W., Kauppila L.I., O'Donnell C.J., Kiel D.P., Hannan M., Polak J.M., et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 103 (2001) 1529-1534
5. Niskanen L.K., Suhonen M., Siitonen O., Lehtinen J.M., and Uusitupa M.I. Aortic and lower limb artery calcification in type 2 (non-insulin-dependent) diabetic patients and non-diabetic control subjects. A five year follow-up study. Atherosclerosis 84 1 (1990) 61-71
6. Fitzgerald P.J., Ports T.A., and Yock P.G. Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation 86 1 (1992) 64-70
7. Wayhs R., Zelinger A., and Raggi P. High coronary artery calcium scores pose an extremely elevated risk for heart events. J Am Coll Cardiol 39 (2002) 225-230
8. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull Jr. W., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Circulation 92 5 (1995) 1355-1374
9. Rutsch F., Schauerte P., Kalhoff H., Petrarulo M., August C., and Diekmann L. Low levels of urinary inorganic pyrophosphate indicating systemic pyrophosphate deficiency in a boy with idiopathic infantile arterial calcification. Acta Paediatr 89 (2000) 1265-1269
10. Rutsch F., Vaingankar S., Johnson K., et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 158 (2001) 543-554
11. Hsu H.H., Camacho N.P., Sun F., Tawfik O., and Aono H. Isolation of calcifying vesicles from high cholesterol-fed rabbits. Atherosclerosis 153 (2000) 337-348
12. Johnson R.C., Leopold J.A., and Loscalzo J. Vascular calcification: Pathobiological mechanisms and clinical implications. Circ Res 99 10 (2006) 1044-1059
13. Boström K., Watson K.E., Horn S., Wortham C., Herman I.M., and Demer L.L. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91 4 (1993) 1800-1809
14. Demer L.L., and Tintut Y. Mineral exploration: Search for the mechanism of vascular calcification and beyond: The 2003 Jeffrey M. Hoeg Award lecture. Arterioscler Thromb Vasc Biol 23 (2003) 1739-1743
15. Terkeltaub R.A. What does cartilage calcification tell us about osteoarthritis?. J Rheumatol 29 (2002) 411-415
16. Luo G., Ducy P., McKee M.D., Pinero G.J., Loyer E., Behringer R.R., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 6620 (1997) 78-81
17. Proudfoot D., Shanahan C.M., and Weissberg P.L. Vascular calcification. New insights into an old problem. J Pathol 185 (1998) 1-3
18. Tintut Y., Patel J., Parhami F., and Demer L.L. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102 (2000) 2636-2642
19. Okawa A., Nakamura I., Goto S., Moriya H., Nakamura Y., and Ikegawa S. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 19 (1998) 271-273
20. Ho A.H., Johnson M.D., and Kingsley D.M. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289 (2000) 265-270
21. Johnson K., Polewski M., van Etten D., and Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol 25 4 (2005) 686-691
22. Rutsch F., Ruf N., Vaingankar S., Toliat M., Suk A., Höhne W., et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 34 (2003) 379-381
23. Ruf N., Uhlenberg B., Terkeltaub R., Nürnberg P., and Rutsch F. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum Mutat 25 1 (2005) 98 [Erratum in
24. Ruf N., Uhlenberg B., Terkeltaub R., Nürnberg P., and Rutsch F. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum Mutat 26 5 (2005) 495-496
25. Numakura C., Yamada M., Ariyasu D., Maesaka A., Kobayashi H., Nishimura G., et al. Genetic and enzymatic analysis for two Japanese patients with idiopathic infantile arterial calcification. J Bone Miner Metab 24 1 (2006) 48-52
26. Cheng K.S., Chen M.R., Ruf N., Lin S.P., and Rutsch F. Generalized arterial calcification of infancy: Different clinical courses in two affected siblings. Am J Med Genet A 136 2 (2005) 210-213
27. El-Maadawy S., Kaartinen M.T., Schinke T., Murshed M., Karsenty G., and McKee M.D. Cartilage Formation and calcification in arteries of mice lacking matrix Gla protein. Connect Tissue Res 44 1 (2003) 272-278
28. Munroe P.B., Olgunturk R.O., Fryns J.P., Van Maldergem L., Ziereisen F., Yuksel B., et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet 21 (1999) 142-144
29. Meier M., Weng L.P., Alexandrakis E., Ruschoff J., and Goeckenjan G. Tracheobronchial stenosis in Keutel syndrome. Eur Respir J 17 (2001) 566-569
30. Zebboudj A.F., Imura M., and Boström K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 277 (2002) 4388-4394
31. Zebboudj A., Shin V., and Boström K. Matrix GLA Protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 90 (2003) 757-765
32. Price P.A., Faus S.A., and Williamson M.K. Warfarin-induced calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20 (2000) 317-327
33. Scatena M., Liaw L., and Giachelli C.M. Osteopontin. A multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27 11 (2007) 2302-2309
34. Baccarini-Contri M., Taparelli F., and Pasquali-Ronchetti I. Osteopontin is a constitutive component of normal elastic fibers in human skin and aorta. Matrix Biol 14 (1994) 553-560
35. Bini A., Mann K.G., Kudryk B.J., and Schoen F.J. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 19 (1999) 1852-1861
36. Wada T., McKee M.D., Steitz S., and Giachelli C.M. Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin. Circ Res 84 2 (1999) 166-178
37. Giachelli C.M., Bae N., Almeida M., Denhardt D.T., Alpers C.E., and Schwartz S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92 4 (1993) 1686-1696
38. Steitz S.A., Speer M.Y., McKee M.D., Liaw L., Almeida M., Yang H., et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 161 (2002) 2035-2046
39. Aikawa E., Nahrendorf M., Sosnovik D., Lok V.M., Jaffer F.A., Aikawa M., et al. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115 3 (2007) 377-386
40. Matsui Y., Rittling S.R., Okamoto H., Inobe M., Jia N., Shimizu T., et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23 6 (2003) 1029-1034
41. Jono S., Peinado C., and Giachelli C.M. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 275 26 (2000) 20197-20203
42. Johnson K., Goding J., Van Etten D., Sali A., Hu S.I., Farley D., et al. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 18 (2003) 994-1004
43. Blair H.C. How the osteoclast degrades bone. Bioessays 20 10 (1998) 837-846
44. Spicer S.S., Lewis S.E., Tashian R.E., and Schulte B.A. Mice carrying a CAR-2 null allele lack carbonic anhydrase II immunohistochemically and show vascular calcification. Am J Pathol 134 (1989) 947-954
45. Cotter M., Connell T., Colhoun E., Smith O.P., and McMahon C. Carbonic anhydrase II deficiency. A rare autosomal recessive disorder of osteopetrosis, renal Tubular acidosis, and cerebral calcification. J Pediatr Hematol Oncol 27 (2005) 115-117
46. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luethy R., et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
47. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234 1 (1997) 137-142
48. Dhore C.R., Cleutjens J.P., Lutgens E., Cleutjens K.B., Geusens P.P., Kitslaar P.J., et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscl Thromb Vasc Biol 21 (2001) 1998-2003
49. Brandström H., Stiger F., Lind L., Kahan T., Melhus H., and Kindmark A. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun 293 (2002) 13-17
50. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247 (1998) 610-615
51. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
52. Orita Y., Yamamoto H., Kohno N., Sugihara M., Honda H., Kawamata S., et al. Role of osteoprotegerin in arterial calcification. Development of new animal model. Arterioscler Thromb Vasc Biol 27 9 (2007) 2058-2064
53. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192 4 (2000) 463-474
54. Bennetti B.J., Scatenai M., Kirki E.A., Rattazzii M., Varoni R.M., Averill M., et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arterioscler Thromb Vasc Biol 26 (2006) 2117-2124
55. Bobryshev Y.V., Lord R.S., and Warren B.A. Calcified deposit formation in intimal thickenings of the human aorta. Atherosclerosis 118 (1995) 9-21
56. Rattazzi M., Bennett B.J., Bea F., Kirk E.A., Ricks J.L., Speer M., et al. Calcification of advanced atherosclerotic lesions in the innominate arteries of ApoE-deficient mice. Potential role of chondrocyte like cells. Arterioscler Thromb Vasc Biol 25 7 (2005) 1420-1425
57. Liu X., Winrow V.R., Horrocks M., and Stevens C.R. Differential expression of TRAIL and its receptors relative to calcification in AAA. Biochem Biophys Res Commun 358 (2007) 18-23
58. Browner W.S., Lui L.Y., and Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86 (2001) 631-637
59. Vik A., Mathiesen E.B., Notø A.T., Sveinbjørnsson B., Brox J., and Hansen J.B. Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. Atherosclerosis 919 1 (2007) 128-134
60. Anand D.V., Lahiri A., Lim E., Hopkins D., and Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47 9 (2006) 1850-1857
61. Morena M., Terrier N., Jaussent I., Leray-Moragues H., Chalabi L., Rivory J.P., et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17 1 (2006) 262-270
62. Ramirez F., and Pereira L. The fibrillins. Int J Biochem Cell Biol 31 (1999) 255-259
63. Pereira L., Lee S.Y., Gayraud B., Andrikopoulos K., Shapiro S.D., Bunton T., et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Pnas 96 (1999) 3819-3823
64. Bunton T.E., Biery N.J., Myers L., Gayraud B., Ramirez F., and Dietz H.C. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res. 88 1 (2001) 37-43
65. Isenburg J.C., Simionescu D.T., Starcher B.C., and Vyavahare N.R. Elastin stabilization for treatment of abdominal aortic aneurysms. Circulation 115 13 (2007) 1729-1737
66. Lindholt J.S. Aneurysmal wall calcification predicts natural history of small abdominal aortic aneurysms. Atherosclerosis 197 2 (2008) 673-678
67. Bailey M., Pillarisetti S., Jones P., Xiao H., Simionescu D., and Vyavahare N. Involvement of matrix metalloproteinases and tenascin-C in elastin calcification. Cardiovasc Pathol 13 3 (2004) 146-155
68. Vyavahare N., Jones P.L., Tallapragada S., and Levy R.J. Inhibition of matrix metalloproteinase activity attenuates tenascin-C production and calcification of implanted purified elastin in rats. Am J Pathol 157 3 (2000) 885-893
69. Pöllänen P.J., Lehtimäki T., Ilveskoski E., Mikkelsson J., Kajander O.A., Laippala P., et al. Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: The Helsinki sudden death study. Atherosclerosis 164 2 (2002) 329-335
70. Basalyga D.M., Simionescu D.T., Xiong W., Baxter B.T., Starcher B.C., and Vyavahare N.R. Elastin degradation and calcification in an abdominal aorta injury model: Role of matrix metalloproteinases. Circulation 110 22 (2004) 3480-3487
71. Qin X., Corriere M.A., Matrisian L.M., and Guzman R.J. Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol 26 7 (2006) 1510-1516
72. Seyama Y., and Wachi H. Atherosclerosis and matrix dystrophy. J Atheroscler Thromb 11 5 (2004) 236-245
73. Wachi H., Sugitani H., Murata H., Nakazawa J., Mecham R.P., and Seyama Y. Tropoelastin inhibits vascular calcification via 67-kDa elastin binding protein in cultured bovine aortic smooth muscle cells. J Atheroscler Thromb 11 3 (2004) 159-166
74. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., et al. Mutation of the mouse klotho gene leads to a syndrome resembling aging. Nature 390 (1997) 45-51
75. Miyamoto K.I., Ito M., Segawa H., and Kuwahata M. Molecular targets of hyperphosphatemia in chronic renal failure. Nephrol Dial Transplant 18 3 (2003) iii79-iii80
76. Arking D.E., Becker D.M., Yanek L.R., Fallin D., Judge D.P., Moy T.F., et al. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 72 (2003) 1154-1161
77. Afrakhte M., Moren A., Jossan S., Itoh S., Sampath K., Westermark B., et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members. Biochem Biophys Res Commun 249 (1998) 505-511
78. Goto K., Kamiya Y., Imamura T., Miyazono K., and Miyazawa K. Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. JBC 282 28 (2007) 20603-20611
79. Galvin K.M., Donovan M.J., Lynch C.A., Meyer R.I., Paul R.J., Lorenz J.N., et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 24 (2000) 171-174
80. Ivandic B.T., Qiao J.H., Machleder D., Liao F., Drake T.A., and Lusis A.J. A locus on chromosome 7 determines myocardial cell necrosis and calcification (dystrophic cardiac calcinosis) in mice. Proc Natl Acad Sci USA 93 11 (1996) 5483-5488
81. Aherrahrou Z., Doehring L., Kaczmarek P.M., Liptau H., Ehlers E.M., Pomarino A., et al. Ultrafine mapping of Dyscalc1 to an 80-kb chromosomal segment on chromosome 7 in mice susceptible for dystrophic calcification. Physiol Genomics 28 2 (2007) 203-212
82. Meng H., Ver I., Che N., Wang X., Wang S.S., Ingram-Drake L., et al. Identification of Abcc6 as the major causal gene for dystrophic cardiac calcification in mice through integrative genomics. Proc Natl Acad Sci USA 104 11 (2007) 4530-4535
83. Ringpfeil F., Lebwohl M.G., Christiano A.M., and Uitto J. Pseudoxanthoma elasticum: Mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci USA 97 11 (2000) 6001-6006
84. Schinke T., Amendt C., Trindl A., Poschke O., Muller-Esterl W., and Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 271 34 (1996) 20789-20796
85. Jahnen-Dechent W., Schinke T., Trindl A., Muller-Esterl W., Sablitzky F., Kaiser S., et al. Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem 272 50 (1997) 31496-31503
86. Heiss A., DuChesne A., Denecke B., Grotzinger J., Yamamoto K., Renne T., et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 278 15 (2003) 13333-13341
87. Reynolds J.L., Skepper J.N., McNair R., Kasama T., Gupta K., Weissberg P.L., et al. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 16 10 (2005) 2920-2930
88. Merx M.W., Schäfer C., Westenfeld R., Brandenburg V., Hidajat S., Weber C., et al. Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol 16 11 (2005) 3357-3364
89. Schäfer C., Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112 3 (2003) 357-366
90. Ketteler M., Bongartz P., Westenfeld R., Wildberger J.E., Mahnken A.H., Bohm R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 361 9360 (2003) 827-833
91. Moe S.M., Reslerova M., Ketteler M., O'neill K., Duan D., Koczman J., et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67 6 (2005) 2295-2304
92. Hendig D., Schulz V., Arndt M., Szliska C., Kleesiek K., and Götting C. Role of serum fetuin-A, a major inhibitor of systemic calcification, in pseudoxanthoma elasticum. Clin Chem 52 2 (2006) 227-234
93. Fiore C.E., Celotta G., Politi G.G., Di Pino L., Castelli Z., Mangiafico R.A., et al. Association of high alpha(2)-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 195 1 (2007) 110-115
94. Mori K., Emoto M., Araki T., Yokoyama H., Teramura M., Lee E., et al. Related articles, association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) 66 2 (2007) 246-250
95. Osawa M., Tian W., Horiuchi H., Kaneko M., and Umetsu K. Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet 116 3 (2005) 146-151
96. Stenvinkel P., Wang K., Qureshi A.R., Axelsson J., Pecoits-Filho R., Gao P., et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 67 6 (2005) 2383-2392
97. Lehtinen A.B., Burdon K.P., Lewis J.P., Langefeld C.D., Ziegler J.T., Rich S.S., et al. Association of alpha2-Heremans-Schmid glycoprotein polymorphisms with subclinical atherosclerosis. J Clin Endocrinol Metab 92 1 (2007) 345-352
98. Fleet J.C., and Hock J.M. Identification of osteocalcin mRNA in nonosteoid tissue of rats and humans by reverse transcription-polymerase chain reaction. J Bone Miner Res 9 (1994) 1565-1573
99. Steitz S.A., Speer M.Y., Curinga G., Yang H.Y., Haynes P., Aebersold R., et al. Smooth muscle cell phenotypic transition associated with calcification. Upregulation of CbfA1 and downregulation of smooth muscle lineage markers. Circ Res 89 (2001) 1147-1154
100. Jono S., McKee M.D., Murry C.E., Shioi A., Nishizawa Y., Mori K., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 (2000) E10-E17
101. Goodman W.G., Goldin J., Kuizon B.D., Shioi A., Nishizawa Y., Mori K., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000) 1478-1483
102. Palmer G., Bonjour J.P., and Caverzasio J. Expression of a newly identified phosphate transporter/retrovirus receptor in human SaOS-2 osteoblast-like cells and its regulation by insulin-like growth factor I. Endocrinology 138 (1997) 5202-5209
103. Palmer G., Guicheux J., Bonjour J.P., and Caverzasio J. Transforming growth factor-β stimulates inorganic phosphate transport and expression of the type II phosphate transporter GlvR-1 in chondrogenic ATDC5 cells. Endocrinology 141 (2000) 2236-2243
104. Suzuki A., Palmer G., Bonjour J.P., and Caverzasio J. Stimulation of sodium-dependent inorganic phosphate transport by activation of Gi/o-protein-coupled receptors by epinephrine in MC3T3-E1 osteoblast-like cells. Bone 28 (2001) 589-594
105. London G.M., Marty C., Marchais S.J., Guerin A.P., Metivier F., de Vernejoul M.C., et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15 (2004) 1943-1951
106. Massry S.G., and Smogorzewski M. Management of vascular calcification in CKD patients. Semin Nephrol 26 1 (2006) 38-41
107. Parhami F., Tintut Y., Ballard A., Fogelman A.M., and Demer L.L. Leptin enhances the calcification of vascular cells: Artery wall as a target of leptin. Circ Res 88 (2001) 954-960
108. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189 1 (2006) 47-60
109. Schoppet M., Al-Fakhri N., Franke F.E., et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 89 8 (2004) 4104-4112
110. Proudfoot D., Skepper J.N., Hegyi L., Bennett M.R., Shanahan C.M., and Weissberg P.L. Apoptosis regulates human vascular calcification in vitro: Evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 87 11 (2000) 1055-1062
111. Bratton D.L., Fadok V.A., Richter D.A., Kailey J.M., Guthrie L.A., and Henson P.M. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem 272 42 (1997) 26159-26165
112. Wu L.N., Genge B.R., Dunkelberger D.G., LeGeros R.Z., Concannon B., and Wuthier R.E. Physicochemical characterization of the nucleational core of matrix vesicles. J Biol Chem 272 7 (1997) 4404-4411
113. Kirsch T., Wang W., and Pfander D. Functional differences between growth plate apoptotic bodies and matrix vesicles. J Bone Miner Res 18 10 (2003) 1872-1881
114. Hruska K.A., Mathew S., and Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 97 2 (2005) 105-114
115. Son B.K., Kozaki K., Iijima K., Eto M., Kojima T., Ota H., et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res 98 8 (2006) 1024-1031
116. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 23 (1998) 14363-14367
117. Kim K.M. Apoptosis and calcification. Scanning Microsc 9 4 (1995) 1137-1178
118. Kockx M.M., De Meyer G.R., Muhring J., Jacob W., Bult H., and Herman A.G. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation 97 23 (1998) 2307-2315
119. Proudfoot D., Davies J.D., Skepper J.N., Weissberg P.L., and Shanahan C.M. Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation 106 24 (2002) 3044-3050
120. O'Rourke R.A., Brundage B.H., Froelicher V.F., Greenland P., Grundy S.M., Hachamovitch R., et al. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 102 1 (2000) 126-140
121. O'Malley P.G., Taylor A.J., Jackson J.L., Doherty T.M., and Detrano R.C. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am J Cardiol 85 8 (2000) 945-948
122. Detrano R.C., Doherty T.M., Davies M.J., and Stary H.C. Predicting coronary events with coronary calcium: Pathophysiologic and clinical problems. Curr Probl Cardiol 25 6 (2000) 374-402
123. Parhami F., Tintut Y., Patel J.K., Mody N., Hemmat A., and Demer L.L. Regulation of vascular calcification in atherosclerosis. Z Kardiol 90 3 (2001) III27-III30
124. Zhang S.H., Reddick R.L., Piedrahita J.A., and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 5081 (1992) 468-471
125. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., and Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92 2 (1993) 883-893
126. Weiss R.M., Ohashi M., Miller J.D., Young S.G., and Heistad D.D. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 114 19 (2006) 2065-2069
127. Towler D.A., Bidder M., Latifi T., Coleman T., and Semenkovich C.F. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 273 46 (1998) 30427-30434
128. Burdon K.P., Langefeld C.D., Beck S.R., Wagenknecht L.E., Carr J.J., Freedman B.I., et al. Association of genes of lipid metabolism with measures of subclinical cardiovascular disease in the Diabetes Heart Study. J Med Genet 42 9 (2005) 720-724
129. Parhami F., Basseri B., Hwang J., Tintut Y., and Demer L.L. High-density lipoprotein regulates calcification of vascular cells. Circ Res 91 7 (2002) 570-576
130. Kizu A., Shioi A., Jono S., Koyama H., Okuno Y., and Nishizawa Y. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. J Cell Biochem 93 5 (2004) 1011-1019
131. Rajamannan N.M., Subramaniam M., Caira F., Stock S.R., and Spelsberg T.C. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 112 9 (2005) I229-I234
132. Rajamannan N.M., Nealis T.B., Subramaniam M., Pandya S., Stock S.R., Ignatiev C.I., et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 111 (2005) 3296-3301
133. Al-Aly Z. Medial vascular calcification in diabetes mellitus and chronic kidney disease: The role of inflammation. Cardiovasc Hematol Disord Drug Targets 7 1 (2007) 1-6
134. Gaillard V., Casellas D., Seguin-Devaux C., Schohn H., Dauca M., Atkinson J., et al. Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis. Hypertension 46 2 (2005) 372-379
135. Bezerra M.C., Calomeni G.D., Caparbo V.F., Gebrim E.S., Rocha M.S., and Pereira R.M. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology (Oxford) 44 12 (2005) 1503-1506
136. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95 11 (2004) 1046-1057
137. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
138. Doherty T.M., Asotra K., Fitzpatrick L.A., Qiao J.H., Wilkin D.J., Detrano R.C., et al. Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads. PNAS 100 (2003) 11201-11206
139. Jeziorska M., McCollum C., and Wooley D.E. Calcification in atherosclerotic plaque of human carotid arteries: Associations with mast cells and macrophages. J Pathol 185 (1998) 10-17
140. Shaalan W.E., Cheng H., Gewertz B., McKinsey J.F., Schwartz L.B., Katz D., et al. Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation. J Vasc Surg 40 2 (2004) 262-269
141. Stenvinkel P., Ketteler M., Johnson R.J., Lindholm B., Pecoits-Filho R., Riella M., et al. IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 67 4 (2005) 1216-1233
142. Radcliff K., Tang T.B., Lim J., Zhang Z., Abedin M., Demer L.L., et al. Insulin-like growth factor-I regulates proliferation and osteoblastic differentiation of calcifying vascular cells via extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase pathways. Circ Res 96 4 (2005) 398-400
143. Tintut Y., Patel J., Territo M., Saini T., Parhami F., and Demer L.L. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation 105 (2002) 650-655
144. Shioi A., Katagi M., Okuno Y., Mori K., Jono S., Koyama H., et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: Roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res 91 1 (2002) 9-16
145. Libby P., Sukhova G., Lee R.T., and Galis Z.S. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 25 (1995) 9-12
146. Hofbauer L.C., Schrader J., Niebergall U., Viereck V., Burchert A., Horsch D., et al. Interleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells. Thromb Haemost 95 4 (2006) 708-714
147. Nadra I., Boccaccini A.R., Philippidis P., Whelan L.C., McCarthy G.M., Haskard D.O., et al. Effect of particle size on hydroxyapatite crystal-induced tumor necrosis factor alpha secretion by macrophages. Atherosclerosis 196 1 (2008) 98-105
148. Anger T., Pohle F.K., Kandler L., Barthel T., Ensminger S.M., Fischlein T., et al. VAP-1, Eotaxin3 and MIG as potential atherosclerotic triggers of severe calcified and stenotic human aortic valves: Effects of statins. Exp Mol Pathol 83 3 (2007) 435-442
149. Ishimura E., Okuno S., Kitatani K., Maekawa K., Izumotani T., Yamakawa T., et al. C-reactive protein is a significant predictor of vascular calcification of both aorta and hand arteries. Semin Nephrol 24 5 (2004) 408-412
150. Schurgers L.J., Spronk H.M., Soute B.A., Schiffers P.M., DeMey J.G., Vermeer C., et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 109 (2007) 2823-2831
151. Schurgers L.J., Aebert H., Vermeer C., Bültmann B., Janzen J., et al. Oral anticoagulant treatment: Friend or foe in cardiovascular disease?. Blood 104 (2004) 3231-3232
152. Koos R., Mahnken A.H., Muhlenbruch G., Brandenburg V., Pflueger B., Wildberger J.E., et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am Coll Cardiol 96 (2005) 747-749
153. London G.M., Guerin A.P., Marchais S.J., Métivier F., Pannier B., Adda H., et al. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 (2003) 1731-1740
154. Wrong O., and Harland C. Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure. Nephron Physiol 107 (2007) 17-33
155. Suki W.N., Zabaneh R., Cangiano J.L., and Reed J. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodiaysis patients. Kidney Int 72 (2007) 1130-1137
156. Lomashvili K.A., Khawandi W., and O'Neill W.C. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 16 (2005) 2495-2500
157. Fleisch H. Bisphosphonates: Mechanisms of action. Endocrinol Rev 19 (1998) 80-100
158. Tamura K., Suzuki Y., Hashiba H., et al. Effect of etidronate on aortic calcification and bone metabolism in calcitriol treated rats with subtotal nephrectomy. J Pharmacol Sci 99 (2005) 89-94
159. Nitta K., Akiba T., Suzuki K., Uchida K., Watanabe R., Majima K., et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiveing long-term hemodialysis. Am J Kidney Dis 44 (2004) 680-688
160. Shimshi M., Abe E., Fisher E.A., Zaidi M., Fallon J.T., et al. Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice. Biochem Biophys Res Commun 328 (2005) 790-793